IP Library Granted Patent US 7,129,062
Granted Patent B2
US 7,129,062 · App. 10/059,561 · Granted Oct 31, 2006

Matrix attachment regions and methods for use thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,129,062
App. No.
10/059,561
Granted
Oct 31, 2006
Kind
B2
Abstract

The present invention relates to compositions and methods for transfecting eukaryotic cells with nucleic acid vectors. In particular, the invention relates to the uses of Matrix Attachment Region (MAR) elements to increase stable and transient transfection efficiency.

Claims (12)

1. A method for transfecting a eukaryotic cell to incorporate a desired gene or portion thereof into said cell wherein the method comprises co-transfecting the cell with unlinked vectors, said unlinked vectors comprising: a first vector comprising a first promoter and a first heterologous gene encoding the desired gene or portion thereof under the transcriptional control of the first promoter, and on first chromatin element, a second unlinked vector comprising a second chromatin element; and a third vector comprising a third vector comprising a second promoter and a second heterologous gene, wherein the chromatin elements are selected from the group consisting of boundary elements, matrix attachment regions, locus control regions and universal chromatin opening elements.

2. The method of claim 1 , wherein said first, second and third vectors are introduced in a molar ratio of between about 1:1.75:5.5 to about 1:1.75:11.

3. The method of claim 1 , wherein the second chromatin element is the same as the first chromatin element.

4. The method of claim 1 , wherein said desired gene is selected from the group consisting of a structural gene and a regulatory gene.

5. The method of claim 1 , wherein the desired gene encodes a polypeptide selected from the group consisting of an antibody, antibody fragment, an antibody light chain and an antibody heavy chain.

6. The method of claim 1 , wherein the desired gene encodes for a human anti-Rhesus D IgG antibody.

7. The method of claim 1 , wherein the first vector further comprises a regulatable gene expression element that permits regulation of expression of the desired gene product by administration of an exogenous molecule.

8. The method of claim 7 , wherein the regulatable gene expression element is the Tet-regulatable element.

9. The method of claim 1 , further comprising contacting said cell with butyrate.

10. The method of claim 9 , wherein the concentration of said butyrate is about 10 mM.

11. The method of claim 1 , wherein said first chromatin element is located 5′ to said promoter and said first heterologous gene.

12. The method of claim 1 , wherein said first chromatin element is located 3′ to said promoter and said first heterologous gene.

Assignments (5)
SECURITY INTEREST Recorded Sep 22, 2022
From: SELEXIS SA
To: LIGAND PHARMACEUTICALS INCORPORATED
Reel/Frame 061187/0661 →
SECURITY INTEREST Recorded Jun 3, 2013
From: SELEXIS SA
To: LIGAND PHARMACEUTICALS INCORPORATED
Reel/Frame 030603/0285 →
RESEARCH LICENSE AND OPTION AGREEMENT Recorded Oct 12, 2007
From: SELEXIS, S.A.
To: GLENMARK PHARMACEUTICALS SA
Reel/Frame 019965/0189 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 10, 2004
From: UNIVERSITE DE LAUSSANNE
To: SELEXIS SA
Reel/Frame 015771/0842 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 4, 2002
From: MERMOD, NICOLAS; ZAHN-ZABAL, MONIQUE; IMHOF, MARKUS; CHATELLARD, PHILLIPPE; GIROD, PIERRE-ALAIN
To: UNIVERSITY OF LAUSANNE
Reel/Frame 013550/0506 →